Status:
ACTIVE_NOT_RECRUITING
Dyspnea and Cardiotoxicity in Multiple Myeloma Patients Who Receive Carfilzomib
Lead Sponsor:
University of Chicago
Conditions:
Multiple Myeloma
Shortness of Breath
Eligibility:
All Genders
18+ years
Brief Summary
This study will explore why some multiple myeloma patients who receive carfilzomib (an anti-cancer medication) experience shortness of breath while others do not. The purpose of this research is to ga...
Eligibility Criteria
Inclusion
- Age ≥ 18
- Confirmed diagnosis of multiple myeloma
- Newly-diagnosed multiple myeloma, or relapsed/refractory multiple myeloma with receipt of 1-3 previous lines of therapy and with a 2-week washout from prior therapy
- Receiving carfilzomib as either standard-of-care therapy or as part of a clinical trial
Exclusion
- Previous receipt of anthracycline chemotherapy
- Previous receipt of carfilzomib
- Four or more previous lines of therapy
- Active pregnancy at the time of enrollment
Key Trial Info
Start Date :
March 22 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 1 2026
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT04827563
Start Date
March 22 2021
End Date
August 1 2026
Last Update
January 22 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Chicago
Chicago, Illinois, United States, 60637